Clinical Trials · NCT02559570
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Forest Laboratories
- Enrollment
- 173
- Start date
- Nov 2015
- Locations
- 62 sites, United States, Canada
- Primary endpoint
- Change From Baseline (CFB) in 4-week Overall Spontaneous Bowel Movement (SBM) Frequency Rate During the Treatment Period